Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BRS051
MIFTS: 63

Breast Disease

Categories: Reproductive diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Breast Disease

About this section

MalaCards integrated aliases for Breast Disease:

Name: Breast Disease 12 15
Breast Diseases 55 43 44 73
Abnormality of the Breast 29

Classifications:

MalaCards categories:
Anatomical: Reproductive diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:3463
MeSH 44 D001941
NCIt 50 C26709
SNOMED-CT 68 79604008
UMLS 73 C0006145
Sources

Summaries for Breast Disease

About this section
MedlinePlus : 43 Most women experience breast changes at some time. Your age, hormone levels, and medicines you take may cause lumps, bumps, and discharges (fluids that are not breast milk). If you have a breast lump, pain, discharge or skin irritation, see your health care provider. Minor and serious breast problems have similar symptoms. Although many women fear cancer, most breast problems are not cancer. Some common breast changes are Fibrocystic breast changes - lumpiness, thickening and swelling, often just before a woman's period Cysts - fluid-filled lumps Fibroadenomas - solid, round, rubbery lumps that move easily when pushed, occurring most in younger women Intraductal papillomas - growths similar to warts near the nipple Blocked milk ducts Milk production when a woman is not breastfeeding NIH: National Cancer Institute

MalaCards based summary : Breast Disease, also known as breast diseases, is related to microglandular adenosis and in situ carcinoma, and has symptoms including pruritus, pelvic pain and exanthema. An important gene associated with Breast Disease is PRLR (Prolactin Receptor), and among its related pathways/superpathways are GPCR Pathway and Circadian entrainment. The drugs Epirubicin and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include breast, skin and testes, and related phenotypes are growth/size/body region and homeostasis/metabolism

Disease Ontology : 12 A thoracic disease that is located in the breast.

Wikipedia : 76 Breast diseases make up a number of conditions. The most common symptoms are a breast mass, breast pain,... more...

Sources

Related Diseases for Breast Disease

About this section

Diseases related to Breast Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 183)
# Related Disease Score Top Affiliating Genes
1 microglandular adenosis 33.0 ERBB2 PGR TP53
2 in situ carcinoma 30.2 BRCA1 ERBB2 ESR1 KRT5 PGR TP53
3 breast cancer 30.2 BRCA1 BRCA2 CTSD CYP19A1 CYP1A1 CYP1B1
4 breast reconstruction 29.9 BRCA1 BRCA2
5 insulin-like growth factor i 29.8 EGF ESR1 IGF1 IGFBP3
6 endometriosis 29.7 CYP19A1 ESR1 ESR2 PGR
7 cervical cancer 29.7 CYP1A1 ERBB2 IGFBP3 KRT5 TP53
8 ductal carcinoma in situ 29.5 BRCA1 BRCA2 CYP19A1 ERBB2 ESR1 KRT5
9 breast fibroadenoma 29.5 CYP19A1 ERBB2 ESR1 PGR
10 gynecomastia 29.5 CYP19A1 ESR1 PGR
11 leiomyoma 29.5 CYP19A1 ESR1 ESR2 PGR
12 cowden disease 29.4 BRCA1 BRCA2 XRCC2
13 mammographic density 29.4 COMT CYP19A1 CYP1A1 CYP1B1 ESR1 IGF1
14 sporadic breast cancer 29.3 BRCA1 BRCA2 ERBB2 ESR1 ESR2 PGR
15 mastitis 11.6
16 diabetic mastopathy 11.2
17 multiple fibroadenomas of the breast 10.9
18 breast abscess 10.8
19 hypertrophy of breast 10.8
20 fat necrosis of breast 10.8
21 infant gynecomastia 10.8
22 breast angiomatosis 10.8
23 endometrial clear cell adenocarcinoma 10.4 CTSD ESR1
24 postmenopausal atrophic vaginitis 10.4 ESR1 ESR2 PRLR
25 slipped capital femoral epiphysis 10.4 IGF1 IGFBP3
26 male reproductive system disease 10.4 ESR2 IGF1 IGFBP3 TP53
27 breast squamous cell carcinoma 10.4 ERBB2 KRT5 TP53
28 male reproductive organ cancer 10.4 ESR2 IGF1 IGFBP3 TP53
29 tonsil cancer 10.4 ERBB2 KRT5 TP53
30 hidradenocarcinoma 10.4 ERBB2 ESR1 KRT5 TP53
31 gastric papillary adenocarcinoma 10.4 ERBB2 TP53
32 colorectal adenoma 10.4 IGF1 IGFBP3 TP53
33 colonic disease 10.4 CTSD ESR1 TP53
34 gastrointestinal adenoma 10.4 CYP1B1 TFF1
35 galactorrhea 10.4 IGF1 PRLR
36 adult hepatocellular carcinoma 10.4 EGF TP53
37 breast cystic hypersecretory carcinoma 10.4 ERBB2 KRT5
38 secondary adrenal insufficiency 10.4 IGF1 IGFBP3
39 stomach disease 10.3 ERBB2 TFF1 TP53
40 malignant spiradenoma 10.3 KRT5 TP53
41 glioblastoma multiforme 10.3 EGF ERBB2 IGF1 TP53
42 respiratory system cancer 10.3 CYP1A1 ERBB2 TP53
43 comedo carcinoma 10.3 ERBB2 ESR1
44 sebaceous adenoma 10.3 EGF ESR1
45 breast adenocarcinoma 10.3 CTSD CYP1A1 EGF ERBB2 ESR1 TP53
46 glassy cell carcinoma of the cervix 10.3 ERBB2 ESR1 PGR
47 endometrium carcinoma in situ 10.3 PGR TP53
48 vestibular gland benign neoplasm 10.3 ESR1 PGR
49 cystadenocarcinoma 10.3 ERBB2 PGR TP53
50 large intestine cancer 10.3 EGF ERBB2 ESR2 IGF1 IGFBP3 TP53

Graphical network of the top 20 diseases related to Breast Disease:



Diseases related to Breast Disease
Sources

Symptoms & Phenotypes for Breast Disease

About this section

UMLS symptoms related to Breast Disease:


pruritus, pelvic pain, exanthema, mastodynia, breast engorgement, nipple discharge, signs and symptoms in breast, other signs and symptoms in breast, breast pain female

MGI Mouse Phenotypes related to Breast Disease:

46 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.44 BRCA1 BRCA2 CTSD CYP19A1 CYP1A1 EGF
2 homeostasis/metabolism MP:0005376 10.44 BRCA1 BRCA2 COMT CTSD CYP19A1 CYP1A1
3 endocrine/exocrine gland MP:0005379 10.42 BRCA1 BRCA2 COMT CTSD CYP19A1 CYP1A1
4 behavior/neurological MP:0005386 10.4 BRCA1 BRCA2 COMT CTSD CYP19A1 ERBB2
5 cellular MP:0005384 10.39 BRCA1 BRCA2 CTSD CYP19A1 ERBB2 ESR1
6 integument MP:0010771 10.35 BRCA1 BRCA2 CTSD CYP19A1 EGF ERBB2
7 cardiovascular system MP:0005385 10.32 BRCA1 COMT CYP19A1 CYP1A1 ERBB2 ESR1
8 digestive/alimentary MP:0005381 10.31 BRCA1 BRCA2 CTSD CYP19A1 EGF ERBB2
9 immune system MP:0005387 10.31 BRCA1 BRCA2 COMT CTSD CYP19A1 CYP1A1
10 hematopoietic system MP:0005397 10.26 BRCA1 BRCA2 COMT CTSD CYP19A1 CYP1A1
11 limbs/digits/tail MP:0005371 10.23 BRCA1 BRCA2 ERBB2 ESR1 ESR2 IGF1
12 neoplasm MP:0002006 10.22 BRCA1 BRCA2 CYP1B1 ERBB2 ESR1 ESR2
13 embryo MP:0005380 10.21 BRCA1 BRCA2 COMT ERBB2 ESR1 PGR
14 adipose tissue MP:0005375 10.2 BRCA1 CYP19A1 ESR1 ESR2 IGF1 IGFBP3
15 nervous system MP:0003631 10.15 BRCA1 BRCA2 COMT CTSD CYP19A1 ERBB2
16 muscle MP:0005369 10.09 BRCA1 CYP19A1 ERBB2 ESR1 ESR2 IGF1
17 normal MP:0002873 10.06 BRCA1 BRCA2 CYP19A1 CYP1A1 EGF ERBB2
18 reproductive system MP:0005389 9.93 BRCA1 BRCA2 COMT CYP19A1 EGF ERBB2
19 renal/urinary system MP:0005367 9.86 BRCA1 COMT CYP19A1 ESR1 ESR2 IGF1
20 respiratory system MP:0005388 9.61 BRCA1 COMT ERBB2 ESR1 ESR2 IGF1
21 skeleton MP:0005390 9.36 BRCA1 BRCA2 CYP19A1 ERBB2 ESR1 ESR2
Sources

Drugs & Therapeutics for Breast Disease

About this section

Drugs for Breast Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1009)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Epirubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 56420-45-2 41867
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 6055-19-2, 50-18-0 2907
3
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-21-8 3385
4
Acetylcholine Approved Phase 4,Phase 3 51-84-3 187
5
Methylene blue Approved, Investigational Phase 4,Phase 2,Not Applicable 61-73-4
6
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 23214-92-8 31703
7
Iron Approved Phase 4,Phase 3,Phase 2,Not Applicable 7439-89-6 23925
8
Povidone-iodine Approved Phase 4,Phase 3 25655-41-8
9
Chlorhexidine Approved, Vet_approved Phase 4,Phase 2,Not Applicable 55-56-1 2713 9552079
10
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 64-17-5 702
11
Povidone Approved Phase 4,Phase 2 9003-39-8
12
Iodine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 7553-56-2 807
13
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33069-62-4 36314
14
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 41575-94-4 10339178 38904 498142
15
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 112809-51-5 3902
16
Toremifene Approved, Investigational Phase 4,Phase 3,Phase 2 89778-26-7 3005573
17
Zoledronic acid Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 118072-93-8 68740
18
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 439-14-5 3016
19
Anastrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 120511-73-1 2187
20
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2 83-43-2 6741
21
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2 2921-57-5
22
Prednisolone Approved, Vet_approved Phase 4,Phase 2 50-24-8 5755
23
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2 302-25-0
24
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
25
Tamoxifen Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 10540-29-1 2733526
26
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 159351-69-6 6442177
27
Exemestane Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 107868-30-4 60198
28
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53123-88-9 46835353 6436030 5284616
29
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
30
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 216974-75-3
31
Capecitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 154361-50-9 60953
32
Pertuzumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 145040-37-5, 380610-27-5 2540
33
Trastuzumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 180288-69-1 9903
34
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 114977-28-5 148124
35
Nitrous oxide Approved, Vet_approved Phase 4,Phase 3 10024-97-2 948
36
Fulvestrant Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 129453-61-8 17756771 104741
37
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
38
Sevoflurane Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 28523-86-6 5206
39 tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40
Vinorelbine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 71486-22-1 60780 44424639
41
Vinblastine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 865-21-4 241903 13342
42
Ondansetron Approved Phase 4,Phase 3,Phase 2,Not Applicable 99614-02-5 4595
43
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 2180-92-9, 38396-39-3 2474
44
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 137-58-6 3676
45
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 2078-54-8 4943
46
Palbociclib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 571190-30-2 11431660 5330286 5005498
47
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 50-03-3
48
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 50-23-7 5754
49
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-61-7 60961
50 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 979-32-8

Interventional clinical trials:

(show top 50) (show all 6955)
# Name Status NCT ID Phase Drugs
1 A Clinical Study on the Efficacy and Safety of the Treatment of Hyperplasia of Mammary Glands With Xiaoru Sanjie Capsule Unknown status NCT02929420 Phase 4 Xiaoru Sanjie capsules;Xiao Yao pills
2 Neoadjuvant ECS Versus ECF in Local Advanced Breast Cancer Unknown status NCT01849380 Phase 4 S-1;5-FU
3 The Use of Botulinum Toxin A in Two-Stage Tissue Expander/ Implant Breast Reconstruction Unknown status NCT01427400 Phase 4 Botulinum Toxin-A;Saline
4 Methylene Blue Intradermal Injection for Sentinel Lymph Node Biopsy for Breast Cancer Patients Unknown status NCT02982148 Phase 4
5 The Efficacy and Safety of PEG-rhG-CSF in Neutropenia After Chemotherapy Unknown status NCT02905916 Phase 4 PEG-rhG-CSF
6 Doxorubicin Hydrochloride Liposome Injection Combination With Cyclophosphamide vs Pirarubicin Combination With Cyclophosphamide in Patients With Locally Advanced Breast Cancer Unknown status NCT02903524 Phase 4 Doxorubicin Hydrochloride Liposome injection and cyclophosphamide;pirarubicin and cyclophosphamide
7 Selective Lymph Node Dissection Using Fluorescent Dye in Node-positive Breast Cancer Unknown status NCT02781259 Phase 4 Indocyanine green
8 Integrated Positron Emission Tomography Magnetic Resonance (PET/MR) of Breast Cancer Unknown status NCT02766530 Phase 4
9 Sienna+® Injection Time Study 4 Arms Unknown status NCT02612870 Phase 4
10 Wound Infections in Breast Cancer Surgery After Preoperative Skin Preparation With Chlorhexidine vs. Povidone-iodine Unknown status NCT02479347 Phase 4 Chlorhexidine;Povidone-Iodine
11 Paclitaxel in Combination With Carboplatin Versus Paclitaxel Plus Epirubicin in Metastatic Breast Cancer Unknown status NCT02207361 Phase 4 Paclitaxel, Carboplatin;Paclitaxel, Epirubicin
12 Weekly and Every 3 Week Administration of Paclitaxel Liposome Injection in Metastatic Breast Cancer Unknown status NCT02142790 Phase 4 paclitaxel liposome injection
13 Proton MR Spectroscopy and 18F-Fluorocholine PET for Breast Cancer Diagnosis Unknown status NCT01956409 Phase 4 18F-FCH;Magnevist
14 Evaluation of Predictive Factors Regarding the Effectivity of Aromatase Inhibitor Therapy (PreFace) Unknown status NCT01908556 Phase 4 Letrozole
15 Benefits of Breast MRI for Predicting of Histopathologic Cell Type of Small Breast Cancer Unknown status NCT01597999 Phase 4
16 Clinical Trial Comparing Outcomes of Breast Conserving Operations With Classic v High-frequency Electrocoagulation Unknown status NCT01216254 Phase 4
17 Extended Adjuvant Treatment With Letrozole in Breast Cancer Who Complete 5 Years of Toremifene Unknown status NCT01072318 Phase 4 Letrozole
18 Evaluate the Relationship of Bone Remodeling Markers for Skeletal Complications in Metastatic Breast Cancer Patients Unknown status NCT00912938 Phase 4 zoledronic acid
19 A Clinical Trial of Paclitaxel Loaded Polymeric Micelle in Patients With Taxane-Pretreated Recurrent Breast Cancer Unknown status NCT00912639 Phase 4 Paclitaxel loaded Polymeric micelle
20 Yunzhi as Dietary Supplement in Breast Cancer Unknown status NCT00647075 Phase 4
21 A Study of Liposomal Doxorubicin in Women With Breast Cancer Exploiting Tissue Doppler Imaging Unknown status NCT00531973 Phase 4 liposomal doxorubicin;epirubicin
22 Study the Role of Positron Emission Mammography in Pre-surgical Planning for Breast Cancer Unknown status NCT00484614 Phase 4
23 The MONET - Study: MR Mammography of Nonpalpable Breast Tumors Unknown status NCT00302120 Phase 4
24 STARS Breast Trial (Study of Anastrozole and Radiotherapy Sequencing Pilot) Unknown status NCT00126360 Phase 4 Timing of Anastrozole in respect to radiotherapy
25 Omega-3 Fatty Acids and Chemotherapy-induced Neuropathy and Inflammation in Breast Cancer Unknown status NCT01049295 Phase 4
26 Does a Single Steroid Injection Reduce the Formation of Postmastectomy Seroma Unknown status NCT00307606 Phase 4 Solu-medrol 125 mg
27 Filgrastim or Pegfilgrastim in Preventing Neutropenia in Women Receiving Chemotherapy Following Surgery for Breast Cancer Unknown status NCT00030758 Phase 4
28 Effects of Tamoxifen in Premenopausal Women With Benign Breast Disease Not at High-Risk of Developing Breast Cancer Completed NCT00999921 Phase 4 Tamoxifen;Evening Primrose Oil
29 Single-shot Pectoral Plane(PECs) Block Versus Continuous Local Anaesthetic Infusion Analgesia or Both PECS Block and Local Anaesthetic Infusion After Breast Surgery: A Prospective Randomised, Double-blind Trial Completed NCT03024697 Phase 4
30 An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis Completed NCT01743560 Phase 4 RAD001;Exemestane
31 Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab Completed NCT02248571 Phase 4 Bevacizumab;Capecitabine;Everolimus;Exemestane
32 The Efficacy and Safety of PEG-rhG-CSF（Pegylated Recombinant Human Granulocyte Colony Stimulating Factor)in Patients With Breast Cancer Who Were Treated With Intensive Chemotherapy Completed NCT02944604 Phase 4 PEG-rhG-CSF
33 PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy Completed NCT02805153 Phase 4 PEG-rhG-CSF;rhG-CSF
34 Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast Cancer Completed NCT02445586 Phase 4 Docetaxel;Pertuzumab;Trastuzumab
35 Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer Completed NCT02287675 Phase 4 Lymphoseek;Sulfur Colloid
36 Sentinel Lymph Node Mapping Post-Injection Site Pain Completed NCT02065232 Phase 4 Tilmanocept;Sulfur Colloid
37 Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast Cancer Completed NCT01961544 Phase 4 Eribulin mesylate
38 Influence of Exceptional Patient Characteristics on Everolimus Exposure Completed NCT01948960 Phase 4 everolimus dose escalation
39 The ODYSSEY TRIAL Phase IV Trial Evaluating the Palliative Benefit of Pamidronate or Zoledronic Acid in Breast Cancer Completed NCT01907880 Phase 4 Pamidronate;Zoledronic acid;placebo
40 Will Preoperative MRI Breast in Women Under 56 Years With Breast Cancer Change Primary Treatment Completed NCT01859936 Phase 4
41 An Open-label, Multi-center Phase â…£ Trial to Evaluate the Efficacy and Safety of Sequential Neoadjuvant Chemotherapy With Docetaxel(Monotaxel®) After Doxorubicin Plus Cyclophosphamide Combination Chemotherapy in Locally Advanced Breast Cancer Completed NCT01660542 Phase 4 Neoadjuvant Chemotherapy with Docetaxel
42 Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer Completed NCT01612871 Phase 4 Tamoxifen, Letrozole , Anastrozole, Exemestane
43 Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or Not Completed NCT01553903 Phase 4 Tamoxifen,;Exemestane;Anastrozole;Letrozole
44 Life Quality and Mental State in Patients With Breast Cancer Completed NCT01458457 Phase 4
45 Wound Infiltration and Breast Cancer Surgery Completed NCT01404377 Phase 4
46 A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Participants With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment Completed NCT01301729 Phase 4 Docetaxel;Paclitaxel;Trastuzumab
47 Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer Completed NCT01231659 Phase 4 Everolimus + Letrozole
48 Comparative Efficiency of Three Regimen, CEFci, CEF and EC as Neoadjuvant Chemotherapy for Primary Breast Cancer Completed NCT01199432 Phase 4 5-FU（intravenous infusion）+epirubicin+cyclophosphamide;5-FU（intravenous bolus）+epirubicin+cyclophosphamide;epirubicin+cyclophosphamide
49 Aromasin® Non-Interventional Study Of Early Invasive Breast Cancer Patients In China Completed NCT01176916 Phase 4 Aromasin (exemestane)
50 Pharmacology of Adjuvant Hormonotherapy in Breast Cancer Completed NCT01127295 Phase 4 Tamoxifen, Letrozole, Anastrozole or Exemestane

Search NIH Clinical Center for Breast Disease

Cochrane evidence based reviews: breast diseases

Sources

Genetic Tests for Breast Disease

About this section

Genetic tests related to Breast Disease:

# Genetic test Affiliating Genes
1 Abnormality of the Breast 29
Sources

Anatomical Context for Breast Disease

About this section

MalaCards organs/tissues related to Breast Disease:

41
Breast, Skin, Testes, Thyroid, Prostate, Bone, Ovary

The Foundational Model of Anatomy Ontology organs/tissues related to Breast Disease:

19
The Breast
Sources

Publications for Breast Disease

About this section

Articles related to Breast Disease:

(show top 50) (show all 1214)
# Title Authors Year
1
Clinical and histologic characteristics of breast cancers in women with previous pathologic diagnosis of benign breast disease in Spain. ( 29517151 )
2018
2
Macrophagic "Crown-like Structures" Are Associated with an Increased Risk of Breast Cancer in Benign Breast Disease. ( 29167285 )
2018
3
Select Choices in Benign Breast Disease: An Initiative of the American Society of Breast Surgeons for the American Board of Internal Medicine Choosing Wisely<sup>Ar</sup> Campaign. ( 29968026 )
2018
4
Infectious and Inflammatory Breast Disease. ( 29298955 )
2018
5
Clinicopathological Analysis of Ultrasound-guided Vacuum-assisted Breast Biopsy for the Diagnosis and Treatment of Breast Disease. ( 29599377 )
2018
6
Modern Approaches to the Surgical Management of Malignant Breast Disease: The Role of Breast Conservation, Complete Mastectomy, Skin- and Nipple-Sparing Mastectomy. ( 29080650 )
2018
7
Efficiency of Imaging Modalities in Male Breast Disease: Can Ultrasound Give Additional Information for Assessment of Gynecomastia Evolution? ( 29322116 )
2018
8
A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease. ( 29453232 )
2018
9
Subtypes of Benign Breast Disease as a Risk Factor for Breast Cancer: A Systematic Review and Meta-Analysis Protocol. ( 29398746 )
2018
10
Ultrasonographic and Mammographic Findings of Male Breast Disease. ( 29708282 )
2018
11
Evaluation of 2 breast cancer risk models in a benign breast disease cohort. ( 29932456 )
2018
12
Correction to: Association between lifestyle, menstrual/reproductive history, and histological factors and risk of breast cancer in women biopsied for benign breast disease. ( 29644560 )
2018
13
The Effects of <i>Berberis Vulgaris</i> Juice on Insulin Indices in Women with Benign Breast Disease: A Randomized Controlled Clinical Trial. ( 29796035 )
2018
14
Ethical Considerations of Medical Photography in the Management of Breast Disease. ( 29978370 )
2018
15
Somatic mutations in benign breast disease tissue and risk of subsequent invasive breast cancer. ( 29872146 )
2018
16
A panel containing PD-1, IL-2Rα, IL-10, and CA15-3 as a biomarker to discriminate breast cancer from benign breast disease. ( 29983594 )
2018
17
Subtypes of Benign Breast Disease as a Risk Factor of Breast Cancer: A Systematic Review and Meta Analyses. ( 30046203 )
2018
18
Preferring fried dishes increases risk of benign breast disease, but not breast cancer. ( 30079899 )
2018
19
Breast fibroadenomas are not associated with increased breast cancer risk in an African American contemporary cohort of women with benign breast disease. ( 30092846 )
2018
20
Male Breast Disease: What the Radiologist Needs to Know. ( 30122313 )
2018
21
Psychosocial stress is associated with benign breast disease in young Chinese women: results from Project ELEFANT. ( 30255453 )
2018
22
Gene expression profiling of the early pathogenesis of wooden breast disease in commercial broiler chickens using RNA-sequencing. ( 30517117 )
2018
23
Recurrent Mondor's breast disease - hormonal contraceptive involvement. ( 30530952 )
2018
24
Ultrasonographic assessment of male breast diseases. ( 29316031 )
2018
25
Demonstration of an algorithm to overcome health system-related barriers to timely diagnosis of breast diseases in rural Zambia. ( 29746541 )
2018
26
MicroRNA expression in pre-treatment plasma of patients with benign breast diseases and breast cancer. ( 29849944 )
2018
27
Association of serum interleukin-10, interleukin-17A and transforming growth factor-α levels with human benign and malignant breast diseases. ( 29904427 )
2018
28
Understanding and Practices of Gynaecologists Related to Breast Cancer Screening, Detection, Treatment and Common Breast Diseases: A Study from India. ( 30051242 )
2018
29
Correction: MicroRNA expression in pre-treatment plasma of patients with benign breast diseases and breast cancer. ( 30174799 )
2018
30
Value of Ultrasound in the Detection of Benign and Malignant Breast Diseases: A Diagnostic Accuracy Study. ( 30210716 )
2018
31
Benign Breast Diseases: An Introduction for the Advanced Practice Nurse. ( 30239503 )
2018
32
Relational autonomy in breast diseases care: a qualitative study of contextual and social conditions of patients' capacity for decision-making. ( 30359251 )
2018
33
Refining Risk Assessment in Women With Benign Breast Disease: An Ongoing Dilemma. ( 28376199 )
2017
34
Down-regulation of hK7 in the sera of breast cancer and benign breast disease patients. ( 28761938 )
2017
35
Association between lifestyle, menstrual/reproductive history, and histological factors and risk of breast cancer in women biopsied for benign breast disease. ( 28643020 )
2017
36
Society of Surgical Oncology Breast Disease Working Group Statement on Prophylactic (Risk-Reducing) Mastectomy. ( 27933411 )
2017
37
Benign breast disease and risk of thyroid cancer. ( 28681104 )
2017
38
Cowden Syndrome: Serendipitous Diagnosis in Patients with Significant Breast Disease. Case Series and Literature Review. ( 27886412 )
2017
39
Diabetic Mastopathy: A Systematic Review of Surgical Management of a Rare Breast Disease. ( 28272124 )
2017
40
Sexual function, anxiety and depression in women with benign breast disease. A case-control study. ( 29267489 )
2017
41
Personal history of proliferative breast disease with atypia and risk of multifocal breast cancer. ( 29266172 )
2017
42
Cancer antigen 15-3, platelet distribution width, and fibrinogen in combination to distinguish breast cancer from benign breast disease in non-conclusive mammography patients. ( 28978076 )
2017
43
Breast disease in men in metropolitan SALo Paulo - Brazil. ( 28741872 )
2017
44
Association between mammographic breast density and histologic features of benign breast disease. ( 29258587 )
2017
45
Metabolic Response to Omega-3 Fatty Acids and Vitamin E Co-Supplementation in Patients with Fibrocystic Breast Disease: A Randomized, Double-Blind, Placebo-Controlled Trial. ( 28846009 )
2017
46
Breast cancer screening: updated recommendations of the Brazilian College of Radiology and Diagnostic Imaging, Brazilian Breast Disease Society, and Brazilian Federation of Gynecological and Obstetrical Associations. ( 28894332 )
2017
47
Body size from birth through adolescence in relation to risk of benign breast disease in young women. ( 28062981 )
2017
48
Fibromatosis, a benign breast disease mimicking carcinoma. A case report. ( 29545999 )
2017
49
The Spectrum of Triple-Negative Breast Disease: High- and Low-Grade Lesions. ( 28736315 )
2017
50
Cumulative risk of breast cancer screening outcomes according to the presence of previous benign breast disease and family history of breast cancer: supporting personalised screening. ( 28427083 )
2017
Sources

Variations for Breast Disease

About this section
Sources

Expression for Breast Disease

About this section
Search GEO for disease gene expression data for Breast Disease.
Sources

Pathways for Breast Disease

About this section

Pathways related to Breast Disease according to GeneCards Suite gene sharing:

(show all 31)
# Super pathways Score Top Affiliating Genes
1
GPCR Pathway 64
Show member pathways
 13.66 BRCA1 BRCA2 EGF ERBB2 ESR1 ESR2
2
Circadian entrainment 37
Show member pathways
 12.95 COMT CTSD ESR1 ESR2 PGR TFF1
3
PI3K-Akt signaling pathway 37
Show member pathways
 12.91 BRCA1 EGF ERBB2 IGF1 PRLR TP53
4
Endometrial cancer 37
Show member pathways
 12.79 BRCA2 EGF ERBB2 IGF1 TP53
5
Pathways in cancer 37
12.72 BRCA2 EGF ERBB2 ESR1 ESR2 IGF1
6
Chks in Checkpoint Regulation 64
Show member pathways
 12.61 BRCA1 BRCA2 ESR1 ESR2 IGF1 TP53
7
Prolactin Signaling Pathway 1 37
Show member pathways
 12.4 CTSD ERBB2 ESR1 ESR2 PRLR
8
DNA Damage Response 1
Show member pathways
 12.3 BRCA1 IGF1 IGFBP3 TP53
9
Glioma 37
Show member pathways
 12.23 BRCA1 BRCA2 EGF ERBB2 ESR1 ESR2
10
Proteoglycans in cancer 37
12.21 ERBB2 ESR1 IGF1 TP53
11
Integrated Breast Cancer Pathway 1
12.06 BRCA1 BRCA2 CYP19A1 ESR1 TP53
12
Development Ligand-independent activation of ESR1 and ESR2 22
Show member pathways
 12.06 EGF ERBB2 ESR1 ESR2 IGF1 TFF1
13
Gastric cancer 37
Show member pathways
 11.94 BRCA1 BRCA2 EGF ERBB2 ESR1 ESR2
14
Glioblastoma Multiforme 64
11.88 EGF IGF1 RHOC TP53
15
Signaling by ERBB4 66
Show member pathways
 11.84 EGF ERBB2 ESR1 PGR PRLR
16
HIF-1 signaling pathway 37
11.83 EGF ERBB2 IGF1
17
Nuclear Receptor transcription pathway 66
Show member pathways
 11.77 ESR1 ESR2 PGR
18
BRCA1 Pathway 64
Show member pathways
 11.73 BRCA1 BRCA2 TP53
19
Bladder cancer 37 1
11.66 EGF ERBB2 TP53
20
Platinum drug resistance 37
11.66 BRCA1 ERBB2 TP53
21
Steroid hormone biosynthesis 37
Show member pathways
 11.63 COMT CYP19A1 CYP1A1 CYP1B1
22
Pathways Affected in Adenoid Cystic Carcinoma 1
11.61 BRCA1 ERBB2 TP53
23
Androstenedione and testosterone biosynthesis and metabolism p.1 22
Show member pathways
 11.49 COMT CYP19A1 CYP1A1
24
Aryl Hydrocarbon Receptor 1
11.43 CYP1A1 CYP1B1 ESR1
25
Ovarian steroidogenesis 37
11.42 CYP19A1 CYP1A1 CYP1B1 IGF1
26
FOXA1 transcription factor network 1
Show member pathways
 11.41 BRCA1 ESR1 TFF1
27
LKB1 signaling events 1
11.36 CTSD ESR1 TP53
28
Estrogen metabolism 1
Show member pathways
 11.2 COMT CYP19A1 CYP1A1 CYP1B1
29
Ovarian Infertility Genes 1
11.13 CYP19A1 ESR2 PGR PRLR
30
Estrogen Receptor Pathway 1
10.78 CYP1A1 CYP1B1 ESR1
31
Aromatase Inhibitor Pathway (Breast Cell), Pharmacodynamics 61
9.93 CYP19A1 ESR1 ESR2
Sources

GO Terms for Breast Disease

About this section

Cellular components related to Breast Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lateral element GO:0000800 9.16 BRCA1 BRCA2
2 insulin-like growth factor ternary complex GO:0042567 8.96 IGF1 IGFBP3
3 insulin-like growth factor binding protein complex GO:0016942 8.62 IGF1 IGFBP3

Biological processes related to Breast Disease according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 regulation of apoptotic process GO:0042981 9.88 BRCA1 ESR1 IGFBP3 TP53
2 positive regulation of gene expression GO:0010628 9.83 BRCA1 EGF ERBB2 IGF1 TP53
3 cell proliferation GO:0008283 9.77 BRCA2 CYP1A1 ERBB2 IGF1 TP53
4 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.71 EGF IGF1 TP53
5 double-strand break repair via homologous recombination GO:0000724 9.7 BRCA1 BRCA2 XRCC2
6 response to estrogen GO:0043627 9.63 BRCA1 COMT ESR1
7 activation of transmembrane receptor protein tyrosine kinase activity GO:0007171 9.57 EGF PRLR
8 estrogen metabolic process GO:0008210 9.56 COMT CYP1B1
9 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.55 IGF1 IGFBP3
10 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.51 ESR1 TP53
11 positive regulation of transcription, DNA-templated GO:0045893 9.5 BRCA1 BRCA2 EGF ESR1 ESR2 IGF1
12 omega-hydroxylase P450 pathway GO:0097267 9.49 CYP1A1 CYP1B1
13 toxin metabolic process GO:0009404 9.48 CYP1A1 CYP1B1
14 mammary gland development GO:0030879 9.43 BRCA2 CYP19A1 PGR
15 negative regulation of ERBB signaling pathway GO:1901185 9.4 EGF ERBB2
16 response to gamma radiation GO:0010332 9.33 BRCA2 TP53 XRCC2
17 chordate embryonic development GO:0043009 9.32 BRCA1 BRCA2
18 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 8.8 BRCA1 BRCA2 TP53

Molecular functions related to Breast Disease according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.73 CYP19A1 CYP1A1 CYP1B1
2 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.71 EGF ERBB2 ESR1
3 monooxygenase activity GO:0004497 9.7 CYP19A1 CYP1A1 CYP1B1
4 steroid hormone receptor activity GO:0003707 9.67 ESR1 ESR2 PGR
5 nuclear receptor activity GO:0004879 9.63 ESR1 ESR2 PGR
6 oxygen binding GO:0019825 9.58 CYP19A1 CYP1A1 CYP1B1
7 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen GO:0016712 9.54 CYP19A1 CYP1A1 CYP1B1
8 steroid binding GO:0005496 9.5 ESR1 ESR2 PGR
9 estrogen receptor activity GO:0030284 9.48 ESR1 ESR2
10 estrogen response element binding GO:0034056 9.43 ESR1 ESR2
11 RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding GO:0038052 9.16 ESR1 ESR2
12 aromatase activity GO:0070330 9.13 CYP19A1 CYP1A1 CYP1B1
13 enzyme binding GO:0019899 9.1 BRCA1 CYP1A1 ESR1 ESR2 PGR TP53
14 metal ion binding GO:0046872 10.29 BRCA1 COMT CYP19A1 CYP1A1 CYP1B1 ESR1
15 protein binding GO:0005515 10.21 BRCA1 BRCA2 COMT CTSD CYP1A1 EGF
16 identical protein binding GO:0042802 10.05 BRCA1 BRCA2 ERBB2 ESR1 ESR2 PGR
Sources

Sources for Breast Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet